Q-omics provides the consensus-scored SAP30 profile across patient tissues and cancer cell-line models. SAP30 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SAP30 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SAP30 protein abundance shows 22,709 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where SAP30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAP30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAP30 survival associations across molecular data types. SAP30 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAP30 RNA expression–survival associations across cancer types. High SAP30 expression shows unfavorable associations in MESO, UVM, KICH, KIRP, LIHC and ACC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SAP30 RNA expression.
This table summarizes SAP30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SAP30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAP30 shows lower tumor expression in THCA and higher tumor expression in KIRC, KIRP, LIHC, COAD and HNSC. The KIRC box plot shows higher SAP30 RNA expression in tumor versus normal tissue (log2 FC = +2.643, t-test p < 0.001).
This table shows molecular features associated with SAP30 in patient tissues and cancer cell lines. In patient samples, SAP30 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SAP30 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
